KTE-X19 CAR T cell therapy in relapsed or refractory mantle-cell lymphoma

Cited by (1,001)

Items 301–400 of 1,001

1. Mechanisms and management of CAR T toxicity
   Christopher James Ferreri, Manisha Bhutani · 2024 · Frontiers in Oncology
2. Infusion and delivery strategies to maximize the efficacy of CAR-T cell immunotherapy for cancers
   Xinyu Gu, Yalan Zhang, Weilin Zhou, Fengling Wang, Feiyang Yan, Haozhan Gao, Wei Wang · 2024 · Experimental Hematology and Oncology
3. Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy
   Preetesh Jain, Loretta J. Nastoupil, Jason R. Westin, Hun Ju Lee, Lucy Jayne Navsaria, Raphael Eric Steiner, Sairah Ahmed, Omar Moghrabi, Onyeka Oriabure, Wendy Chen et al. · 2020 · British Journal of Haematology
4. Gene expression profiling-based risk prediction and profiles of immune infiltration in diffuse large B-cell lymphoma
   Selin Merdan, Kritika Subramanian, Turgay Ayer, Johan Van Weyenbergh, Andrés Chang, Jean Louise Koff, Christopher R. Flowers · 2021 · Blood Cancer Journal
5. T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects
   Spyridoula Vasileiou, Premal Lulla, Ifigeneia Tzannou, Ayumi Watanabe, Manik Kuvalekar, Wendy L. Callejas, Mrinalini Bilgi, Tao Wang, Meng‐Fen Wu, Rammurti T. Kamble et al. · 2021 · Journal of Clinical Oncology
6. Nano-drug delivery systems for T cell-based immunotherapy
   Rui P. Li, Zhimin Chen, Juyi Li, Zhifei Dai, Yingjie Yu · 2022 · Nano Today
7. Ibrutinib improves the efficacy of anti‐CD19‐CAR T‐cell therapy in patients with refractory non‐Hodgkin lymphoma
   Meijing Liu, Haobin Deng, Juan Mu, Qing Li, Yedi Pu, Yili Jiang, Qi Deng, Zhengzi Qian · 2021 · Cancer Science
8. The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma
   Changying Jiang, Yang Liu, Alexa A Jordan, Joseph Mitchell McIntosh, Yijing Li, Yuxuan Che, Katti Jessen, Brian Joseph Lannutti, Michael L. Wang · 2021 · Journal of Hematology & Oncology
9. Primary Effusion Lymphoma: A Clinicopathologic Perspective
   Diamone Gathers, Emily A. Galloway, Katalin Kelemen, Allison Claire Rosenthal, Sarah E. Gibson, Javier L Munoz · 2022 · Cancers
10. Acute and delayed cytopenias following CAR T-cell therapy: an investigation of risk factors and mechanisms
    Jennifer N. Brudno, Danielle A. Natrakul, Norris Lam, Alina Dulau‐Florea, Constance M. Yuan, James N. Kochenderfer · 2022 · Leukemia & lymphoma/Leukemia and lymphoma
11. Cancer Immunotherapy and Delivery System: An Update
    Ming Jun Yang, Olamide Tosin Olaoba, Chunye Zhang, Eric T. Kimchi, Kevin F. Staveley-O’Carroll, Guangfu Li · 2022 · Pharmaceutics
12. Self-regulating CAR-T cells modulate cytokine release syndrome in adoptive T-cell therapy
    Meng-Yin Lin, Eunwoo Nam, Ryan M. Shih, Amanda Shafer, Amber Bouren, Melanie Ayala Ceja, Caitlin M. Harris, Mobina Khericha, Kenny Vo, Minsoo Kim et al. · 2024 · The Journal of Experimental Medicine
13. Dual-targeting CAR T cells for B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma
    Gustavo de Oliveira Canedo, Claire Roddie, Persis Jal Amrolia · 2024 · Blood Advances
14. Complex neural-immune interactions shape glioma immunotherapy
    Kun-Wei Song, Michael K. Lim, Michelle Monje · 2025 · Immunity
15. Multifunctional theranostic nanoparticles for multi-modal imaging-guided CAR-T immunotherapy and chemo-photothermal combinational therapy of non-Hodgkin's lymphoma
    Bowen Shi, Dan Li, Weiwu Yao, Wenfang Wang, Jiang Jiang, Ruiheng Wang, Fuhua Yan, Han Liu, Huan Zhang, Jian Ye · 2022 · Biomaterials Science
16. Impact of Cytomegalovirus Replication in Patients with Aggressive B Cell Lymphoma Treated with Chimeric Antigen Receptor T Cell Therapy
    Ester Márquez‐Algaba, Gloria Iacoboni, Berta Pernas, Juliana Esperalba, Ibai Los Arcos, Vı́ctor Navarro, Arnau Monforte, Francisco Beas, Adaia Albasanz‐Puig, Cecilia del Carmen Carpio et al. · 2022 · Transplantation and Cellular Therapy
17. Homology-independent targeted insertion (HITI) enables guided CAR knock-in and efficient clinical scale CAR-T cell manufacturing
    H. Balke-Want, V. Keerthi, N. Gkitsas, A. Mancini, G. Kurgan, C. Fowler, Peng Xu, Xi-Kun Liu, K. Asano, Sunny Patel et al. · 2023 · Molecular Cancer
18. Incidence and outcomes of cytomegalovirus reactivation after chimeric antigen receptor T-cell therapy
    Rick Y. Lin, Anthony D. Anderson, Yoichiro Natori, Mohammed A. Raja, Michele Ileana Morris, Antonio Jiménez, Amer Beitinjaneh, Trent Peng Wang, Mark S. Goodman, Lazaros J. Lekakis et al. · 2024 · Blood Advances
19. Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL
    Gregory W. Roloff, Ibrahim Taha Aldoss, Noam Edward Kopmar, Chenyu Lin, Simone E. Dekker, Vishal K Gupta, Timothy Edward O'Connor, Nikeshan Jeyakumar, Ibrahim N. Muhsen, Yannis K. Valtis et al. · 2024 · Journal of Clinical Oncology
20. CAR T-cell therapy and critical care
    Anna Sarah Messmer, Yok‐Ai Que, Christoph Josef Schankin, Yara Banz, Ulrike Bacher, Urban Novak, Thomas Pabst · 2021 · Wiener klinische Wochenschrift
21. Targeting the Microenvironment for Treating Multiple Myeloma
    Peter Neumeister, Eduard Schulz, Katrin Pansy, Marta Szmyra, Alexander J. A. Deutsch · 2022 · International Journal of Molecular Sciences
22. CAR T-Cell Therapy in the Older Person: Indications and Risks
    Geoffrey Shouse, Alexey Valeryevich Danilov, Andy Artz · 2022 · Current Oncology Reports
23. Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies
    Ali Keshavarz, Ali Salehi, Setareh Khosravi, Yasaman Shariati, Navid Nasrabadi, Mohammad Saeed Kahrizi, Sairan Maghsoodi, Amirhossein Mardi, Ramyar Azizi, Samira Jamali et al. · 2022 · Stem Cell Research & Therapy
24. Synthetic manipulation of the cancer-immunity cycle: CAR-T cell therapy
    Nathan Singh, Marcela Valderrama Maus · 2023 · Immunity
25. How I Manage: Pathophysiology and Management of Toxicity of Chimeric Antigen Receptor T-Cell Therapies
    Patrick Michael Reagan, Sattva Swarup Neelapu · 2021 · Journal of Clinical Oncology
26. Nanoparticles for Enhanced Adoptive T Cell Therapies and Future Perspectives for CNS Tumors
    Preethi Bala Balakrishnan, Elizabeth E. Sweeney · 2021 · Frontiers in Immunology
27. Role of bridging therapy during chimeric antigen receptor T cell therapy
    Shakthi Bhaskar, Bhagirathbhai Dholaria, Salyka M. Sengsayadeth, Bipin N. Savani, Olalekan O. Oluwole · 2021 · eJHaem
28. Updated Indications for Immune Effector Cell Therapy: 2023 Guidelines from the American Society for Transplantation and Cellular Therapy.
    A. Kanate, N. Majhail, Zachariah M. DeFilipp, B. Dhakal, Bhagirathbhai R. Dholaria, B. Hamilton, A. Herrera, Y. Inamoto, Tania Jain, M. Perales et al. · 2023 · Transplantation and Cellular Therapy
29. CAR-macrophage versus CAR-T for solid tumors: The race between a rising star and a superstar
    Kun Chen, Minling Liu, Jiancheng Wang, Shuo Fang · 2023 · Biomolecules and Biomedicine
30. Advances in CAR‐Engineered Immune Cell Generation: Engineering Approaches and Sourcing Strategies
    Zhaozhao Chen, Yu Hu, Heng Mei · 2023 · Advanced Science
31. ReCARving the future: bridging CAR T-cell therapy gaps with synthetic biology, engineering, and economic insights
    Alaa Mohammed Ali, John F. DiPersio · 2024 · Frontiers in Immunology
32. Comprehensive Review of Early and Late Toxicities in CAR T-Cell Therapy and Bispecific Antibody Treatments for Hematologic Malignancies
    Ayrton Bangolo, Behzad Amoozgar, Charlene Mansour, Lili Zhang, Sarvarinder Kaur Gill, Andrew Ip, Christina Cho · 2025 · Cancers
33. CAR T-Cell Therapy: An Update for Radiologists
    Justin G. Yoon, Daniel Arnold Smith, Sree H. Tirumani, Paolo F. Caimi, Nikhil H. Ramaiya · 2021 · American Journal of Roentgenology
34. CAR‐T therapy: Prospects in targeting cancer stem cells
    Xiaoyue Cui, Rui Liu, Lian Duan, Dan Cao, Qiaoling Zhang, Aijie Zhang · 2021 · Journal of Cellular and Molecular Medicine
35. Tumor-Associated Neutrophil Extracellular Traps Regulating Nanocarrier-Enhanced Inhibition of Malignant Tumor Growth and Distant Metastasis
    Haoyuan Yin, Hongdan Lu, Yaokun Xiong, Lu Ye, Chuanhui Teng, Xiang Cao, Shengnan Li, Shanbo Sun, Wentao Liu, Wei Lv et al. · 2021 · ACS Applied Materials & Interfaces
36. Fertility and CAR T-cells: Current practice and future directions
    John A. Ligon, Abigail Fry, Jacqueline Y. Maher, Toni Foley, Sara K. Silbert, Bonnie Yates, Veronica Gomez‐Lobo, Lori S. Wiener, Nirali N. Shah · 2022 · Transplantation and Cellular Therapy
37. Trogocytosis and fratricide killing impede MSLN-directed CAR T cell functionality
    Esther Schoutrop, Stefanie Renken, Isabella Micallef Nilsson, Paula Hahn, Thomas Poiret, Rolf W. Kiessling, Stina Linnea Wickström, Jonas Mattsson, Isabelle Magalhaes · 2022 · OncoImmunology
38. Innovations in cancer immunotherapy: A comprehensive overview of recent breakthroughs and future directions
    Chou‐Yi Hsu, Harikumar Pallathadka, Saade Abdalkareem Jasim, Jasur Alimdjanovich Rizaev, Dmitry Olegovich Bokov, Ahmed M. Hjazi, Shriya Mahajan, Yasser Fakri Mustafa, Beneen Husseen, Mohammed Abed Jawad · 2024 · Critical Reviews in Oncology/Hematology
39. The promise and perils of immunotherapy
    Stefanie Lesch, Saar I. Gill · 2021 · Blood Advances
40. SMAD7 expression in CAR-T cells improves persistence and safety for solid tumors
    Sixin Liang, Rui Zheng, Baile Zuo, Jia Li, Yiyi Wang, Yujie Han, Hao Dong, Xiaojuan Zhao, Yiting Zhang, Pengju Wang et al. · 2024 · Cellular and Molecular Immunology
41. The Burden of Invasive Fungal Disease Following Chimeric Antigen Receptor T-Cell Therapy and Strategies for Prevention
    Jessica S Little, Eleftheria Kampouri, Daniel Z. P. Friedman, Todd P McCarty, George R. Thompson, Dimitrios P. Kontoyiannis, José A. Vázquez, John W. Baddley, Sarah Page Hammond · 2024 · Open Forum Infectious Diseases
42. The resistance mechanisms and treatment strategies of BTK inhibitors in B-cell lymphoma
    Wang, Haoran, Zhang, Wentao, Yang, Jingyi, Zhou, Keshu · 2021 · Hematological Oncology
43. Natural Receptor- and Ligand-Based Chimeric Antigen Receptors: Strategies Using Natural Ligands and Receptors for Targeted Cell Killing
    Gianna M. Branella, Harold Trent Spencer · 2021 · Cells
44. Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up
    Pier Luigi Zinzani, Armando Santoro, Giuseppe Gritti, Pauline Brice, Paul M. Barr, John G. Kuruvilla, David Cunningham, Justin Paul Kline, Nathalie A. Johnson, Neha Mehta–Shah et al. · 2023 · Blood Advances
45. Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated Patients
    Victoria Panagiota, Johanna Franziska Kerschbaum, Olaf Penack, Catarina M. Stein, Christopher Maximilian Arends, Christian Koenecke, Paulina M. Strzelecka, Arnold Kloos, Laura Wiegand, Alina Lasch et al. · 2023 · HemaSphere
46. Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia
    Justin C. Boucher, Bishwas Shrestha, Paresh Vishwasrao, Mark B. Leick, Estelle V. Cervantes, Tayyebb Ghafoor, Kayla M. Reid, Kristen Spitler, Bin Yu, Brian Christopher Betts et al. · 2023 · Molecular Therapy — Oncolytics
47. Toxicities, intensive care management, and outcome of chimeric antigen receptor T cells in adults: an update
    Mathieu Bellal, Jolan Malherbe, Gandhi Laurent Damaj, Damien du Cheyron · 2024 · Critical Care
48. Chimeric Antigen Receptor (CAR) T-Cell Therapy in Hematologic Malignancies: Clinical Implications and Limitations
    Philipp Blüm, Sabine Käyser · 2024 · Cancers
49. Enhancing pediatric access to cell and gene therapies
    Crystal Lee Mackall, Catherine M. Bollard, Nancy Goodman, Casey Carr, Rebecca Gardner, Rayne Helen Rouce, Elena Sotillo, Rich Stoner, Fyodor D. Urnov, Alan S. Wayne et al. · 2024 · Nature Medicine
50. Recent clinical researches and technological development in TIL therapy
    Satoko Matsueda, Lei Chen, Hongmei Li, Hui Qing Yao, Fuli Yu · 2024 · Cancer Immunology Immunotherapy
51. Safety and efficacy of CAR-T cell therapy in patients with autoimmune diseases: a systematic review
    Lakshmi Prasanna Vaishnavi Kattamuri, Bhavesh Mohan Lal, Nikhil Vojjala, Mansi Jain, Kunal Sharma, Siddharth Jain, Samer Al Hadidi · 2025 · Rheumatology International
52. Turning ‘Cold’ tumors ‘Hot’: immunotherapies in sarcoma
    Jeffrey D. Rytlewski, Mohammed M. Milhem, Varun Monga · 2021 · Annals of Translational Medicine
53. Induced Pluripotent Stem Cells (iPSCs) Provide a Potentially Unlimited T Cell Source for CAR-T Cell Development and Off-the-Shelf Products
    Muhammad Sadeqi Nezhad, Meghdad Abdollahpour‐Alitappeh, Behzad Rezaei, Mahboubeh Yazdanifar, Alexander Marcus Seifalian · 2021 · Pharmaceutical Research
54. Development of CAR T Cell Therapy in Children—A Comprehensive Overview
    Michael Boettcher, Alexander Joechner, Ziduo Li, Sile Fiona Yang, Patrick Schlegel · 2022 · Journal of Clinical Medicine
55. Engineering Next-Generation CAR-T Cells: Overcoming Tumor Hypoxia and Metabolism
    Torahito A. Gao, Yvonne Y. Chen · 2022 · Annual Review of Chemical and Biomolecular Engineering
56. Cytopenias following anti-CD19 chimeric antigen receptor (CAR) T cell therapy: a systematic analysis for contributing factors
    Yuan Xia, Jue Zhang, Jing Li, Lina Zhang, Jianyong Li, Lei Fan, Lijuan Chen · 2022 · Annals of Medicine
57. Next‐generation chimeric antigen receptors for T‐ and natural killer‐cell therapies against cancer
    Ye Li, Katayoun Rezvani, Hind Rafei · 2023 · Immunological Reviews
58. In Vivo Cellular Expansion of Lisocabtagene Maraleucel and Association With Efficacy and Safety in Relapsed/Refractory Large B‐Cell Lymphoma
    Ken Ogasawara, James F. Lymp, Timothy R. Mack, Justine Dell’Aringa, Chang‐pin Huang, Jeff Smith, Leanne Peiser, Ana Kostić · 2022 · Clinical Pharmacology & Therapeutics
59. Treatment approaches for patients with TP53-mutated mantle cell lymphoma
    Thomas Eliot Lew, Adrian G. Minson, Michael John Dickinson, Sasanka M. Handunnetti, Piers A. Blombery, Amit S. Khot, Mary Ann Anderson, David Ritchie, Constantine Si Lun Tam, John Francis Seymour · 2023 · The Lancet Haematology
60. A systematic review and meta-analysis of CD22 CAR T-cells alone or in combination with CD19 CAR T-cells
    Nathan Fergusson, Komal Adeel, Natasha K. Kekre, Harold L. Atkins, Kevin Anthony Hay · 2023 · Frontiers in Immunology
61. Transient responses and significant toxicities of anti-CD30 CAR T cells for CD30+ lymphomas: results of a phase 1 trial
    Jennifer N. Brudno, Danielle A. Natrakul, Jeremiah Xavier Karrs, Nisha Patel, Roberto Maass‐Moreno, Mark A. Ahlman, Lekha Mikkilineni, Jennifer Mann, David F. Stroncek, Steven Lorenz Highfill et al. · 2023 · Blood Advances
62. Advances in molecular targeted drugs in combination with CAR-T cell therapy for hematologic malignancies
    Yuxian Huang, Yinjie Qin, Yingzhi He, Dezhi Qiu, Yeqin Zheng, Jiayue Wei, Lenghe Zhang, Dong‐Hua Yang, Yuhua Li · 2024 · Drug Resistance Updates
63. Therapeutic advances in the targeting of ROR1 in hematological cancers
    Adrian-Bogdan Tigu, Raluca Andrada Munteanu, Cristian Silviu Moldovan, Rareş Drulă, Dávid Kegyes, Radu Andrei Tomai, Vlad Moisoiu, Gabriel Ghiaur, Ciprian Tomuleasa, Hermann Einsele et al. · 2024 · Cell Death Discovery
64. Immunotherapy in Hematologic Malignancies: Emerging Therapies and Novel Approaches
    Ji‐Yoon Noh, Huiyun Seo, Jungwoon Lee, Haiyoung Jung · 2020 · International Journal of Molecular Sciences
65. Delivery technologies to engineer natural killer cells for cancer immunotherapy
    Rakan D. El-Mayta, Zijing Zhang, Alex G. Hamilton, Michael J. Mitchell · 2021 · Cancer Gene Therapy
66. The Potential Role of the Intestinal Micromilieu and Individual Microbes in the Immunobiology of Chimeric Antigen Receptor T-Cell Therapy
    Maria‐Luisa Schubert, Roman Rohrbach, Michael W. Schmitt, Christoph K. Stein‐Thoeringer · 2021 · Frontiers in Immunology
67. Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigens
    Michael S. Hwang, Michelle S. Miller, Puchong Thirawatananond, Jacqueline Douglass, Katharine M. Wright, Emily Han-Chung Hsiue, Brian J. Mog, Tihitina Y. Aytenfisu, Michael B. Murphy, P. Aitana Azurmendi et al. · 2021 · Nature Communications
68. CAR-T cells, from principle to clinical applications
    Estelle Bourbon, Hervé Ghesquières, Emmanuel Bachy · 2021 · Bulletin du Cancer
69. The potential of pirtobrutinib in multiple B-cell malignancies
    Jeffrey Lee Jensen, Anthony R. Mato, Camila Peña, Lindsey Elizabeth Roeker, Catherine Callaghan Coombs · 2022 · Therapeutic Advances in Hematology
70. Identifying Early Infections in the Setting of CRS With Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL
    Kai Rejeski, Viktoria Blumenberg, Gloria Iacoboni, Lucía López‐Corral, Soraya Kharboutli, Rafael Hernani, Agnese Petrera, Niklas Müller, Friederike Hildebrand, Lisa Frölich et al. · 2023 · HemaSphere
71. Critically Ill Patients Treated for Chimeric Antigen Receptor-Related Toxicity: A Multicenter Study*
    Cristina Gutierrez, Anne Rain T. Brown, Heather P. May, Amer Beitinjaneh, R. Scott Stephens, Prabalini Rajendram, Joseph L. Nates, Stephen M. Pastores, Ananda Dharshan, Alice Gallo de Moraes et al. · 2021 · Critical Care Medicine
72. Regulatory T cells (Tregs) in lymphoid malignancies and the impact of novel therapies
    Kamira Karen Maharaj, Angimar Uriepero, Eva Sahakian, Javier A. Pinilla-Ibarz · 2022 · Frontiers in Immunology
73. Beyond youth: Understanding CAR T cell fitness in the context of immunological aging
    Julia Han Noll, Bruce L. Levine, Carl H. June, Joseph A. Fraietta · 2023 · Seminars in Immunology
74. Next-Generation Implementation of Chimeric Antigen Receptor T-Cell Therapy Using Digital Health
    Rahul Kumar Banerjee, Nina D. Shah, Adam Paul Dicker · 2021 · JCO Clinical Cancer Informatics
75. Engineered T Cells: CAR T Cell Therapy and Beyond
    Patrick Connor Johnson, Jeremy S. Abramson · 2022 · Current Oncology Reports
76. Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment
    Allison Marie Bock, Grzegorz S. Nowakowski, Yucai Wang · 2022 · Current Treatment Options in Oncology
77. Practical aspects of chimeric antigen receptor T-cell administration: From commercial to point-of-care manufacturing
    Núria Martínez‐Cibrián, Marta Español‐Rego, Mariona Pascal, Julio Delgado, Valentín Ortiz‐Maldonado · 2022 · Frontiers in Immunology
78. Lymphodepletion chemotherapy in chimeric antigen receptor-engineered T (CAR-T) cell therapy in lymphoma
    Marta Canelo‐Vilaseca, Mohamad Sabbah, Roberta Di Blasi, Caterina Cristinelli, Anna Maria Sureda, Sophie Caillat‐Zucman, Catherine Thiéblemont · 2025 · Bone Marrow Transplantation
79. Redirecting T Cells against Epstein–Barr Virus Infection and Associated Oncogenesis
    Christian Münz · 2020 · Cells
80. CAR‐T TREK through the lymphoma universe, to boldly go where no other therapy has gone before
    Guido Ghilardi, Peter Brændstrup, Elise A. Chong, Stephen J. Schuster, Jakub Svoboda, Marco Ruella · 2020 · British Journal of Haematology
81. Cardiotoxicity Associated with Anti-CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Recognition, Risk Factors, and Management
    Ethan Alexander Burns, Cesar Gentille Sanchez, Barry H. Trachtenberg, Sai Ravi Pingali, Kartik Anand · 2021 · Diseases
82. Radiation and CAR T-cell Therapy in Lymphoma: Future Frontiers and Potential Opportunities for Synergy
    Penny Fang, Jillian Rebecca Gunther, Susan Y. Wu, Bouthaina Shbib Dabaja, Loretta J. Nastoupil, Sairah Ahmed, Sattva Swarup Neelapu, Chelsea Camille Pinnix · 2021 · Frontiers in Oncology
83. ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma
    Pashna N. Munshi, Mehdi Hamadani, Ambuj Kumar, Peter Dreger, Jonathan W. Friedberg, Martin H. Dreyling, Brad S. Kahl, Mats Jerkeman, Mohamed A. Kharfan‐Dabaja, Frederick Lundry Locke et al. · 2021 · Bone Marrow Transplantation
84. CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: a preclinical model and initial clinical experience
    Maria Lia Palomba, David Augustus Qualls, Sébastien Monette, Shenon Sethi, Ahmet Doǧan, Mikhail Roshal, Brigitte Sénéchal, Xiuyan Wang, Isabelle Rivière, Michel Sadelain et al. · 2022 · Journal for ImmunoTherapy of Cancer
85. Donor T cells for CAR T cell therapy
    Tiffany C. Y. Tang, Ning Xu, Robert E. Nordon, Michelle Haber, Kenneth P. Micklethwaite, Alla Dolnikov · 2022 · Biomarker Research
86. Influence of TP53 Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era
    Edit Anna Porpaczy, Philipp Wohlfarth, Oliver Königsbrügge, Werner Rabitsch, Cathrin Skrabs, Philipp Bernhard Staber, Nina Worel, Leonhard Müllauer, Ingrid Simonitsch‐Klupp, Christoph Kornauth et al. · 2021 · Cancers
87. Complexities in comparing the impact of costimulatory domains on approved CD19 CAR functionality
    Richard M. Smith, Rhine R. Shen · 2023 · Journal of Translational Medicine
88. The physical landscape of CAR-T synapse
    Yiwei Xiong, Kendra A. Libby, Xiaolei Su · 2023 · Biophysical Journal
89. Infections in haematology patients treated with CAR-T therapies: A systematic review and meta-analysis
    Gemma K. Reynolds, Beatrice Sim, Tim D. Spelman, Ashmitha Thomas, Anthony Longhitano, Mary Ann Anderson, Karin Thursky, Monica A. Slavin, Benjamin W. Teh · 2023 · Critical Reviews in Oncology/Hematology
90. Diagnosis and management of mantle cell lymphoma: A British Society for Haematology Guideline
    Toby Andrew Eyre, Mark J. Bishton, Rory McCulloch, Maeve A O'Reilly, Robin Sanderson, Geetha Menon, Sunil Iyengar, David John Lewis, Jonathan Lambert, Kim Linton et al. · 2023 · British Journal of Haematology
91. CAR-T cell combination therapies in hematologic malignancies
    Delian Zhou, Xiaojian Zhu, Yi Qun Xiao · 2024 · Experimental Hematology and Oncology
92. CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML
    Harrison J. Silva, Grace A. Martin, Filippo Birocchi, Marc Wehrli, Michael C. Kann, Valentina M. Supper, Aiyana Parker, Charlotte Graham, Alexandra Bratt, Amanda A. Bouffard et al. · 2024 · Blood
93. Cross-Talk Between Cancer and Its Cellular Environment—A Role in Cancer Progression
    Eliza Turlej, Aleksandra Domaradzka, Justyna Radzka, Dominika Drulis‐Fajdasz, Julita Kulbacka, Agnieszka Gizak · 2025 · Cells
94. Blastoid Mantle Cell Lymphoma
    Preetesh Jain, Michael L. Wang · 2020 · Hematology/Oncology Clinics of North America
95. Is There Still a Role for Allogeneic Transplantation in the Management of Lymphoma?
    Nirav Niranjan Shah, Mehdi Hamadani · 2021 · Journal of Clinical Oncology
96. Advanced Therapies and Regulatory Framework in Different Areas of the Globe: Past, Present, and Future
    Cleila Guimarães Pimenta Bosio, Vitória Loureiro Bettiol, Thuany Alencar‐Silva, Octávio Luiz Franco, Robert Edward Pogue, Juliana Lott Carvalho, Maria Sueli Soares Felipe · 2021 · Clinical Therapeutics
97. Time 2EVOLVE: predicting efficacy of engineered T-cells – how far is the bench from the bedside?
    Sònia Guedan, Maik Luu, Delphine Ammar, Paula Barbao, Chiara Bonini, Philippe Bousso, Christian J. Buchholz, Monica Casucci, Biagio De Angelis, Emmanuel Donnadieu et al. · 2022 · Journal for ImmunoTherapy of Cancer
98. Resistance against anti-CD19 and anti-BCMA CAR T cells: Recent advances and coping strategies
    Pınar Ataca Atilla, Erden Atilla · 2022 · Translational Oncology
99. Impact of Preemptive Use of Tocilizumab on Chimeric Antigen Receptor T Cell Outcomes in Non-Hodgkin Lymphoma
    Chiara De Philippis, Daniele Mannina, Laura Giordano, Elena Costantini, Simona Marcheselli, Jacopo Mariotti, Barbara Sarina, Daniela Taurino, Armando Santoro, Stéfania Bramanti · 2023 · Transplantation and Cellular Therapy
100. Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use
     Veit Bücklein, Ariel Perez Perez, Kai Rejeski, Gloria Iacoboni, Vindi Jurinović, Udo Holtick, Olaf Penack, Soraya Kharboutli, Viktoria Blumenberg, Josephine Ackermann et al. · 2023 · HemaSphere